HUE073077T2 - Anti-GPRDC5D antitestek, bispecifikus antigénkötõ molekulák, amelyek megkötik a GPRDC5D -t és a CD3-at, valamint azok felhasználása - Google Patents
Anti-GPRDC5D antitestek, bispecifikus antigénkötõ molekulák, amelyek megkötik a GPRDC5D -t és a CD3-at, valamint azok felhasználásaInfo
- Publication number
- HUE073077T2 HUE073077T2 HUE17745951A HUE17745951A HUE073077T2 HU E073077 T2 HUE073077 T2 HU E073077T2 HU E17745951 A HUE17745951 A HU E17745951A HU E17745951 A HUE17745951 A HU E17745951A HU E073077 T2 HUE073077 T2 HU E073077T2
- Authority
- HU
- Hungary
- Prior art keywords
- gprc5d
- antigen binding
- binding molecules
- bind
- bispecific antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364811P | 2016-07-20 | 2016-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE073077T2 true HUE073077T2 (hu) | 2025-12-28 |
Family
ID=60992891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17745951A HUE073077T2 (hu) | 2016-07-20 | 2017-07-20 | Anti-GPRDC5D antitestek, bispecifikus antigénkötõ molekulák, amelyek megkötik a GPRDC5D -t és a CD3-at, valamint azok felhasználása |
Country Status (42)
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| EA201891753A1 (ru) | 2016-02-03 | 2019-01-31 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| WO2018035710A1 (en) * | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| SG11201907321TA (en) * | 2017-02-07 | 2019-09-27 | Daiichi Sankyo Co Ltd | Anti-gprc5d antibody and molecule comprising the antibody |
| PT3703750T (pt) | 2017-11-01 | 2025-01-17 | Memorial Sloan Kettering Cancer Center | Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes |
| TWI829667B (zh) * | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| JP7337079B2 (ja) * | 2018-02-15 | 2023-09-01 | マクロジェニクス，インコーポレーテッド | 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用 |
| UA130542C2 (uk) * | 2018-05-16 | 2026-03-18 | Янссен Байотек, Інк. | Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта |
| CN111116753A (zh) * | 2018-10-30 | 2020-05-08 | 上海泰因生物技术有限公司 | 一种双特异性抗体的制备方法 |
| MA54078A (fr) | 2018-11-01 | 2021-09-15 | Juno Therapeutics Inc | Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| EP3873937A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| WO2020052692A2 (en) * | 2018-12-04 | 2020-03-19 | Novartis Ag | Binding molecules against cd3 and uses thereof |
| UA128001C2 (uk) * | 2018-12-21 | 2024-03-06 | Ф. Хоффманн-Ля Рош Аг | Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули |
| BR112021013824A2 (pt) * | 2019-01-18 | 2021-12-14 | Janssen Biotech Inc | Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| SG11202111943UA (en) | 2019-07-02 | 2021-11-29 | Hutchinson Fred Cancer Res | Recombinant ad35 vectors and related gene therapy improvements |
| CN114174338A (zh) | 2019-07-31 | 2022-03-11 | 豪夫迈·罗氏有限公司 | 与gprc5d结合的抗体 |
| CA3248329A1 (en) * | 2019-07-31 | 2025-11-29 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
| EP4069742A1 (en) * | 2019-12-06 | 2022-10-12 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
| PH12022500012A1 (en) * | 2020-03-30 | 2023-04-03 | Daiichi Sankyo Co Ltd | Bispecific antibody |
| WO2022013819A1 (en) * | 2020-07-17 | 2022-01-20 | Janssen Biotech, Inc. | Anti-idiotypic antibodies against anti-gprc5d antibodies |
| EP4213945A1 (en) * | 2020-09-16 | 2023-07-26 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
| EP4274851B1 (en) * | 2021-01-05 | 2025-11-26 | Lanova Medicines Development Co., Ltd. | Anti-gprc5d monoclonal antibodies and uses thereof |
| PT4274851T (pt) * | 2021-01-05 | 2026-02-13 | Lanova Medicines Dev Co Ltd | Anticorpos monoclonais anti-gprc5d e utilizações destes |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| JP2024507180A (ja) | 2021-02-16 | 2024-02-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体 |
| US20250074996A1 (en) * | 2021-02-19 | 2025-03-06 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF |
| JP7714675B2 (ja) | 2021-03-24 | 2025-07-29 | ヤンセン バイオテツク，インコーポレーテツド | ＣＤ７９ｂ、ＣＤ２０、及びＣＤ３を標的とする三重特異性抗体 |
| TW202309522A (zh) | 2021-05-11 | 2023-03-01 | 美商健生生物科技公司 | 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物 |
| WO2022247804A1 (zh) * | 2021-05-23 | 2022-12-01 | 上海祥耀生物科技有限责任公司 | 抗gprc5d抗体、其制备方法与用途 |
| WO2023030272A1 (zh) * | 2021-08-30 | 2023-03-09 | 原启生物科技(上海)有限责任公司 | 抗gprc5d抗原结合蛋白及其用途 |
| AU2022380155A1 (en) | 2021-11-03 | 2024-06-20 | Janssen Biotech, Inc. | Corticosteriod reduction in treatment with anti-cd38 antibodies |
| CN118159565A (zh) * | 2021-11-05 | 2024-06-07 | 正大天晴药业集团股份有限公司 | 结合gprc5d的抗体及其用途 |
| WO2023115347A1 (zh) * | 2021-12-21 | 2023-06-29 | 上海驯鹿生物技术有限公司 | 靶向gprc5d的全人源抗体 |
| AU2022418639A1 (en) * | 2021-12-21 | 2024-08-01 | Shanghai Iaso Biotechnology Co., Ltd. | Fully human antibody targeting gprc5d and chimeric antigen receptor (car) and use thereof |
| WO2023173272A1 (zh) * | 2022-03-15 | 2023-09-21 | 上海驯鹿生物技术有限公司 | 靶向gprc5d的全人源嵌合抗原受体(car)及其应用 |
| CN116375868A (zh) * | 2021-12-31 | 2023-07-04 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| CN116375867A (zh) * | 2021-12-31 | 2023-07-04 | 康源博创生物科技(北京)有限公司 | 抗gprc5d抗体及其应用 |
| WO2023125888A1 (zh) * | 2021-12-31 | 2023-07-06 | 山东先声生物制药有限公司 | 一种gprc5d抗体及其应用 |
| JP2025504795A (ja) * | 2022-01-10 | 2025-02-19 | ナンチン リーズ バイオラブス カンパニー，リミティド | 抗体及びその用途 |
| EP4471065A4 (en) * | 2022-01-29 | 2025-11-26 | Carsgen Life Sciences Co Ltd | GPRC5D ANTIBODY AND ITS USE |
| MX2024011128A (es) | 2022-03-14 | 2024-09-18 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico. |
| EP4507790A1 (en) | 2022-04-11 | 2025-02-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN119278217A (zh) * | 2022-05-27 | 2025-01-07 | 德琪(杭州)生物有限公司 | 新型抗gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子以及其用途 |
| IL317463A (en) * | 2022-06-06 | 2025-02-01 | Shandong Simcere Biopharmaceutical Co Ltd | Multispecific antibodies targeting BCMA, GPRC5D and T cells and their application |
| US20260116966A1 (en) * | 2022-06-30 | 2026-04-30 | Keymed Biosciences (Chengdu) Co., Ltd. | Development and use of novel multispecific tumor inhibitor |
| CN119698434A (zh) * | 2022-07-21 | 2025-03-25 | 山东先声生物制药有限公司 | 抗gprc5d纳米抗体及其应用 |
| JP2025525937A (ja) | 2022-08-05 | 2025-08-07 | ジュノー セラピューティクス インコーポレイテッド | Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体 |
| CN116003598B (zh) * | 2022-08-30 | 2024-04-26 | 苏州缔码生物科技有限公司 | 靶向人gprc5d的重组人源化单克隆抗体及其应用 |
| JP2025529210A (ja) | 2022-09-01 | 2025-09-04 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法 |
| US20260078195A1 (en) * | 2022-09-09 | 2026-03-19 | Beijing Mabworks Biotech Co., Ltd | Multi-specific antibody binding to bcma, gprc5d and cd3, and use thereof |
| TW202430211A (zh) | 2022-10-10 | 2024-08-01 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法 |
| TW202423969A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法 |
| TW202423970A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法 |
| CN117924485A (zh) * | 2022-10-25 | 2024-04-26 | 上海祥耀生物科技有限责任公司 | 一种抗gprc5d的多特异性抗体 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| JP2026504737A (ja) * | 2022-12-22 | 2026-02-09 | ヤンセン ファーマシューティカ エヌ．ベー． | 抗体－ポリヌクレオチドコンジュゲートを調製する方法 |
| TW202434644A (zh) | 2023-02-07 | 2024-09-01 | 大陸商上海齊魯製藥研究中心有限公司 | 三特異性抗原結合分子及其應用 |
| CN120857940A (zh) | 2023-02-17 | 2025-10-28 | 瑞泽恩制药公司 | 对cd3/taa双特异性抗体有反应的诱导型nk细胞 |
| CN120916780A (zh) | 2023-02-28 | 2025-11-07 | 詹森生物科技公司 | 包含双特异性gprc5d/cd3抗体的组合物 |
| KR20250164808A (ko) * | 2023-03-22 | 2025-11-25 | 바이오프런트 쎄라퓨틱스 (베이징) 컴퍼니 리미티드 | Gprc5d에 결합하는 나노바디 및 이의 용도 |
| KR20260006599A (ko) * | 2023-04-28 | 2026-01-13 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | G 단백질 결합 수용체를 표적으로 하는 이중특이성 항체 |
| KR20260013450A (ko) * | 2023-05-16 | 2026-01-28 | 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 | 이중 특이적 항원 결합 분자 및 이의 응용 |
| WO2024246856A1 (en) | 2023-06-01 | 2024-12-05 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
| TW202502826A (zh) | 2023-06-06 | 2025-01-16 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｇｐｒｃ５ｄ／ｂｃｍａ／ｃｄ３三特異性抗體的製備及其用途 |
| WO2024251242A1 (en) * | 2023-06-09 | 2024-12-12 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel antibodies targeting cd3 and another target and uses thereof |
| WO2025002251A1 (zh) * | 2023-06-28 | 2025-01-02 | 浙江博锐生物制药有限公司 | 抗gprc5d抗体及其医药用途 |
| CN121586730A (zh) * | 2023-07-20 | 2026-02-27 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| WO2025056013A1 (zh) * | 2023-09-13 | 2025-03-20 | 江苏恒瑞医药股份有限公司 | 一种包含特异性结合gprc5d和cd3的双特异性抗体的药物组合物 |
| WO2025059362A1 (en) | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025094085A1 (en) | 2023-10-31 | 2025-05-08 | Janssen Biotech, Inc. | Combination regimens for treating multiple myeloma |
| WO2025122929A1 (en) * | 2023-12-08 | 2025-06-12 | Janssen Biotech, Inc. | Gprc5d antibodies with enhanced effector function and uses thereof |
| WO2025134050A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma |
| WO2025134049A1 (en) | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis |
| WO2025147545A1 (en) | 2024-01-03 | 2025-07-10 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids and related methods and uses |
| CN117843788B (zh) * | 2024-01-09 | 2025-02-11 | 四川大学 | 一种抗gprc5d的抗体及其多特异性抗体和相关应用 |
| CN118108846B (zh) * | 2024-02-04 | 2024-11-26 | 四川大学华西医院 | 靶向GPRC5D同种异体CAR-γδT细胞的制备及应用 |
| WO2025194478A1 (en) * | 2024-03-22 | 2025-09-25 | Biofront Ltd | Antibodies binding to cd3 and gprc5d, and uses thereof |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025259877A1 (en) * | 2024-06-12 | 2025-12-18 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting gprc5d and cd3 and methods of use thereof |
| WO2026001924A1 (zh) * | 2024-06-24 | 2026-01-02 | 南京蓬勃生物科技有限公司 | 结合gprc5d的抗体及其用途 |
| WO2026001931A1 (zh) * | 2024-06-24 | 2026-01-02 | 南京蓬勃生物科技有限公司 | Gprc5d结合分子及其用途 |
| US20260014252A1 (en) | 2024-07-11 | 2026-01-15 | Regeneron Pharmaceuticals, Inc. | GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof |
| US12545726B1 (en) | 2025-07-22 | 2026-02-10 | Integral Molecular, Inc. | Compositions and methods related to GPRC5D binding agents and variants thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU4347701A (en) | 2000-03-01 | 2001-09-12 | Corixa Corp | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US20050019320A1 (en) * | 2001-12-27 | 2005-01-27 | Eiji Sugaru | Remedies for anorexia or lifestyle-related diseases and method of screening the same |
| WO2005086568A2 (en) * | 2004-01-26 | 2005-09-22 | Morphosys Ag | Anti-icam-1 human antibodies and uses thereof |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| EP2285833B1 (en) * | 2008-05-16 | 2014-12-17 | Ablynx N.V. | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| DK2352763T4 (da) | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| US20110293619A1 (en) | 2008-10-01 | 2011-12-01 | Micromet Ag | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY |
| EP2352765B1 (en) | 2008-10-01 | 2018-01-03 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
| ES2705714T3 (es) | 2008-10-31 | 2019-03-26 | Janssen Biotech Inc | Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones |
| BRPI1008532B1 (pt) | 2009-02-12 | 2021-12-14 | Janssen Biotech, Inc | Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| FR2994803B1 (fr) | 2012-08-30 | 2016-02-26 | Oreal | Modulation de la forme des fibres keratiniques |
| LT2961771T (lt) | 2013-02-26 | 2020-03-10 | Roche Glycart Ag | Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams |
| EP3699195A3 (en) | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| MA40609B1 (fr) | 2014-09-05 | 2020-05-29 | Janssen Pharmaceutica Nv | Agents de liaison cd123 et leurs utilisations |
| PH12017500442B1 (en) | 2014-09-09 | 2023-05-24 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| BR112017011932A8 (pt) * | 2014-12-05 | 2022-11-08 | Memorial Sloan Kettering Cancer Center | Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso |
| IL256242B2 (en) | 2015-06-22 | 2024-09-01 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| MX2018002043A (es) | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| EA201891084A1 (ru) | 2015-11-02 | 2019-10-31 | Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение | |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| SG11201907321TA (en) | 2017-02-07 | 2019-09-27 | Daiichi Sankyo Co Ltd | Anti-gprc5d antibody and molecule comprising the antibody |
| US11970542B2 (en) | 2017-11-08 | 2024-04-30 | Fred Hutchinson Cancer Center | Bispecific antibodies specific for treating hematological malignancies |
| EP4213945A1 (en) | 2020-09-16 | 2023-07-26 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
| TW202309522A (zh) | 2021-05-11 | 2023-03-01 | 美商健生生物科技公司 | 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物 |
-
2017
- 2017-07-18 TW TW106123980A patent/TWI781108B/zh active
- 2017-07-19 AR ARP170102018A patent/AR109499A1/es active IP Right Grant
- 2017-07-19 UY UY0001040770A patent/UY40770A/es not_active Application Discontinuation
- 2017-07-19 UY UY0001040768A patent/UY40768A/es active IP Right Grant
- 2017-07-19 UY UY0001037340A patent/UY37340A/es active IP Right Grant
- 2017-07-19 UY UY0001040769A patent/UY40769A/es active IP Right Grant
- 2017-07-19 UY UY0001040672A patent/UY40672A/es active IP Right Grant
- 2017-07-20 KR KR1020197004695A patent/KR102572091B1/ko active Active
- 2017-07-20 PE PE2024000391A patent/PE20240884A1/es unknown
- 2017-07-20 SM SM20250356T patent/SMT202500356T1/it unknown
- 2017-07-20 PE PE2019000228A patent/PE20190392A1/es unknown
- 2017-07-20 MA MA45712A patent/MA45712B1/fr unknown
- 2017-07-20 EP EP25189388.9A patent/EP4643953A3/en active Pending
- 2017-07-20 EP EP17745951.8A patent/EP3487882B1/en active Active
- 2017-07-20 FI FIEP17745951.8T patent/FI3487882T3/fi active
- 2017-07-20 CR CR20190025A patent/CR20190025A/es unknown
- 2017-07-20 RS RS20250945A patent/RS67235B1/sr unknown
- 2017-07-20 CN CN202211621205.2A patent/CN116333133A/zh active Pending
- 2017-07-20 PL PL17745951.8T patent/PL3487882T3/pl unknown
- 2017-07-20 NZ NZ750152A patent/NZ750152A/en unknown
- 2017-07-20 EA EA201990346A patent/EA201990346A1/ru unknown
- 2017-07-20 MD MDE20190628T patent/MD3487882T2/ro unknown
- 2017-07-20 HU HUE17745951A patent/HUE073077T2/hu unknown
- 2017-07-20 LT LTEPPCT/US2017/042982T patent/LT3487882T/lt unknown
- 2017-07-20 JP JP2019502647A patent/JP7292200B2/ja active Active
- 2017-07-20 HR HRP20251181TT patent/HRP20251181T1/hr unknown
- 2017-07-20 ES ES17745951T patent/ES3042078T3/es active Active
- 2017-07-20 SG SG11201900468YA patent/SG11201900468YA/en unknown
- 2017-07-20 PT PT177459518T patent/PT3487882T/pt unknown
- 2017-07-20 MX MX2019000825A patent/MX2019000825A/es unknown
- 2017-07-20 BR BR112019001055-6A patent/BR112019001055A2/pt active IP Right Grant
- 2017-07-20 IN IN201917002488A patent/IN201917002488A/en unknown
- 2017-07-20 IL IL264334A patent/IL264334B2/en unknown
- 2017-07-20 IL IL298277A patent/IL298277A/en unknown
- 2017-07-20 CN CN201780057838.6A patent/CN109715667B/zh active Active
- 2017-07-20 AU AU2017299673A patent/AU2017299673B2/en active Active
- 2017-07-20 DK DK17745951.8T patent/DK3487882T3/da active
- 2017-07-20 KR KR1020237028767A patent/KR102811945B1/ko active Active
- 2017-07-20 SI SI201731627T patent/SI3487882T1/sl unknown
- 2017-07-20 WO PCT/US2017/042982 patent/WO2018017786A2/en not_active Ceased
- 2017-07-20 NZ NZ790480A patent/NZ790480A/en unknown
- 2017-07-20 CA CA3031472A patent/CA3031472A1/en active Pending
- 2017-07-20 KR KR1020257016487A patent/KR20250073578A/ko active Pending
- 2017-07-20 US US15/655,086 patent/US10562968B2/en active Active
-
2019
- 2019-01-18 MX MX2023006449A patent/MX2023006449A/es unknown
- 2019-01-18 CL CL2019000146A patent/CL2019000146A1/es unknown
- 2019-01-18 NI NI201900005A patent/NI201900005A/es unknown
- 2019-01-18 MX MX2024001615A patent/MX2024001615A/es unknown
- 2019-01-21 PH PH12019500152A patent/PH12019500152A1/en unknown
- 2019-02-05 CO CONC2019/0001114A patent/CO2019001114A2/es unknown
- 2019-02-19 ZA ZA2019/01066A patent/ZA201901066B/en unknown
- 2019-02-19 EC ECSENADI201912075A patent/ECSP19012075A/es unknown
-
2020
- 2020-02-03 US US16/779,713 patent/US11685777B2/en active Active
-
2022
- 2022-10-28 JP JP2022173361A patent/JP7469432B2/ja active Active
-
2023
- 2023-01-20 US US18/157,800 patent/US11884722B2/en active Active
- 2023-12-04 US US18/528,157 patent/US20240343796A1/en active Pending
-
2024
- 2024-01-31 JP JP2024013728A patent/JP2024054176A/ja active Pending
- 2024-02-14 CL CL2024000444A patent/CL2024000444A1/es unknown
- 2024-03-08 AR ARP240100592A patent/AR132097A2/es unknown
- 2024-04-04 CL CL2024001015A patent/CL2024001015A1/es unknown
- 2024-04-04 CL CL2024001016A patent/CL2024001016A1/es unknown
- 2024-07-22 AU AU2024205021A patent/AU2024205021A1/en active Pending
- 2024-09-13 AR ARP240102459A patent/AR133827A2/es unknown
- 2024-09-13 AR ARP240102458A patent/AR133826A2/es unknown
-
2026
- 2026-01-12 FI FIC20265003C patent/FIC20265003I1/fi unknown
- 2026-01-12 NO NO2026001C patent/NO2026001I1/no unknown
- 2026-01-12 LT LTPA2026501C patent/LTPA2026501I1/lt unknown
- 2026-01-13 FR FR26C1002C patent/FR26C1002I1/fr active Active
- 2026-01-14 NL NL301360C patent/NL301360I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901066B (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
| IL259082A (en) | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof | |
| CY2023007I1 (el) | Anti-bcma αντισωματα, διειδικα μορια συνδεσης αντιγονου που συνδεουν bcma και cd3, και χρησεις αυτων | |
| ZA202006983B (en) | Bispecific antibody constructs binding dll3 and cd3 | |
| IL266599A (en) | Anti-met antibodies, met-binding protein binding molecules, and methods of using them | |
| HUE061419T2 (hu) | ANTI-PSMA antitestek, PSMA-t és CD3-at megkötõ bispecifikus antigénkötõ molekulák és azok alkalmazása | |
| IL256872A (en) | Bispecific antibody constructs that bind to egfrviii and cd3 and uses thereof | |
| IL256873A (en) | Constructs for bispecific antibodies that bind to masotilin and cd3 and uses thereof | |
| DK2897981T3 (da) | Anti-CD3-antistoffer, bispecifikke antigenbindingsmolekyler, der binder CD3 og CD20, samt anvendelser deraf | |
| HK40007243A (en) | Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof |